Austria-based biotechnology company Themis Bioscience on Tuesday announced the appointment of two new members to leadership roles, Philippe Dro and Christian Mandl.
The appointments follow the successful completion of a Phase I clinical trial of the company's Chikungunya vaccine.
Dr Dro will join the board of directors, while Dr Mandl has been named the chair for the company’s scientific advisory board.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze